Caris Life Sciences, Inc. income statement

In fiscal 2025, Caris Life Sciences, Inc. reported revenue of $812m, up 97.0% on the year before, operating income of $45.1m (a 5.6% margin) and net income of −$68.1m, or −$3.22 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Caris Life Sciences, Inc.: income statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	306	412	812	990
Research and development	117	114	102	117
Selling and marketing	143	153	168	184
General and administrative	149	169	225	235
Operating income	−320	−257	45	153
Interest expense	32	50	57	47
Income before tax	−341	−282	−68	105
Income tax	0	0	0	−0
Net income	−341	−282	−68	105
Diluted EPS	−$2.65	−$2.13	−$3.22	—
Diluted shares (average)	175m	177m	167m	—
EBITDA	−271	−208	68	174

US$ millions unless shown otherwise. Fiscal quarters.

Caris Life Sciences, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	102	130	121	181	217	293	216	264
Research and development	28	27	23	25	22	32	31	32
Selling and marketing	37	38	40	42	41	44	45	54
General and administrative	41	43	52	64	52	57	60	67
Operating income	−61	−37	−58	−18	33	88	5	27
Interest expense	14	13	13	19	14	11	13	9
Income before tax	−68	−37	−103	−72	24	82	−1	−1
Income tax	0	0	0	0	0	0	−0	0
Net income	−68	−37	−103	−72	24	82	−1	−1
Diluted EPS	−$2.59	−$1.74	−$3.57	−$7.97	$0.08	$1.61	$0.00	$0.00
EBITDA	−50	−28	−51	−12	38	93	10	33

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CAI vs INNV CAI vs CRVL CAI vs PNTG

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Caris Life Sciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Caris Life Sciences, Inc.